


The miR-139-5p regulates proliferation of supratentorial paediatric low-grade gliomas by targeting the PI3K/AKT/mTORC1 signalling

G. Catanzaro*, Z. M. Besharatt, E. Miele‡, M. Chiacchiarinit,‡, A. Po†, A. Carai§, C. E. Marras§, M. Antonelli¶, M. Badiali**, A. Raso††, S. Mascelli††, D. Schrimpf‡‡,§§, D. Stichel§§, M. Tartaglia¶¶, D. Capper‡‡,§§,***, A. von Deimling‡‡,§§, F. Giangaspero¶¶,†††, A. Mastronuzzi‡‡‡, F. Locatelli‡‡‡,§§§ and E. Ferretti*,††† 

*Department of Experimental Medicine, †Department of Molecular Medicine, Sapienza University, ‡Center for Life NanoScience@Sapienza, IIT, §Neurosurgery Unit, Department of Neuroscience and Neurorehabilitation, Bambino Gesù Children's Hospital, IRCCS, ¶Department of Radiological, Oncological and Pathological Science, Sapienza University, Rome, **Bone Marrow Transplantation Unit, Microcitomico Children's Hospital, Cagliari, ††Giannina Gaslini Institute, Genoa, Italy, ‡‡Department of Neuropathology, Heidelberg University, §§German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Clinical Cooperation Unit (CCU) Neuropathology, Heidelberg, Germany, ¶¶Genetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, Rome, Italy, ***Department of Neuropathology, Charité Universitätsmedizin Berlin, Berlin, Germany, †††IRCCS Neuromed, Pozzilli, ‡‡‡Department of Hematology/Oncology and Stem Cell Transplantation, Bambino Gesù Children's Hospital, IRCCS, Rome, and §§§University of Pavia, Pavia, Italy

G. Catanzaro, Z. M. Besharat, E. Miele, M. Chiacchiarini, A. Po, A. Carai, C. E. Marras, M. Antonelli, M. Badiali, A. Raso, S. Mascelli, D. Schrimpf, D. Stichel, M. Tartaglia, D. Capper, A. von Deimling, F. Giangaspero, A. Mastronuzzi, F. Locatelli, E. and Ferretti (2018) *Neuropathology and Applied Neurobiology* 44, 687–706

The miR-139-5p regulates proliferation of supratentorial paediatric low-grade gliomas by targeting the PI3K/AKT/mTORC1 signalling

Aims: Paediatric low-grade gliomas (pLGGs) are a heterogeneous group of brain tumours associated with a high overall survival: however, they are prone to recur and supratentorial lesions are difficult to resect, being associated with high percentage of disease recurrence. Our aim was to shed light on the biology of pLGGs. **Methods:** We performed microRNA profiling on 45 fresh-frozen grade I tumour samples of various histological classes, resected from patients aged ≤16 years. We identified 93 microRNAs specifically dysregulated in tumours as compared to non-neoplastic brain tissue. Pathway analysis of the microRNAs signature revealed PI3K/AKT signalling

as one of the centrally enriched oncogenic signalling. To date, activation of the PI3K/AKT pathway in pLGGs has been reported, although activation mechanisms have not been fully investigated yet. **Results:** One of the most markedly down-regulated microRNAs in our supratentorial pLGGs cohort was miR-139-5p, whose targets include the gene encoding the PI3K's (phosphatidylinositol 3-kinase) catalytic unit, *PIK3CA*. We investigated the role of miR-139-5p in regulating PI3K/AKT signalling by the use of human cell cultures derived from supratentorial pLGGs. MiR-139-5p overexpression inhibited pLGG cell proliferation and decreased the phosphorylation of PI3K target AKT

Correspondence: Elisabetta Ferretti or Felice Giangaspero, Viale Regina Elena, 291, 00161 Rome, Italy. Tel: +39 0649255135 or +39 0649979175; Fax: +39 0649255660 or +39 0649979175; E-mails: elisabetta.ferretti@uniroma1.it or felice.giangaspero@uniroma1.it
Current address: Evelina Miele, Department of Hematology/Oncology and Stem Cell Transplantation, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy

© 2018 The Authors. *Neuropathology and Applied Neurobiology* published by John Wiley & Sons Ltd on behalf of British Neuropathological Society.

687

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

and phosphorylated-p70 S6 kinase (p-p70 S6K), a hallmark of PI3K/AKT/mTORC1 signalling activation. The effect of miR-139-5p was mediated by PI3K inhibition, as suggested by the decrease in proliferation and phosphorylation of AKT and p70 S6K after

treatment with the direct PI3K inhibitor LY294002. **Conclusions:** These findings provide the first evidence that down-regulation of miR-139-5p in supratentorial pLGG drives cell proliferation by derepressing PI3K/AKT signalling.

Keywords: microRNAs, miR-139-5p, paediatric low-grade gliomas, patients' derived primary cells, PI3K/AKT/mTORC1, Supratentorial

Introduction

The most commonly diagnosed brain tumours in children are low-grade gliomas (LGGs). Paediatric LGGs (pLGGs) include different entities, as defined by the revised World Health Organization (WHO) classification of central nervous system tumours, which is based on both histological and molecular features [1]. The vast majority of pLGGs are pilocytic astrocytomas (PAs), and they are the ones that have been studied most thoroughly. These tumours are driven by dysregulated signalling through the MAPK/ERK pathway [2]. Less is known about the biological characteristics of less common pLGGs which include, among others, gangliogliomas (GGs), dysembryoplastic neuroepithelial tumours (DNETs) and angiocentric gliomas (AGs).

The location of pLGGs has a major impact on outcome since it determines the tumour's resectability. Infratentorial pLGGs, which occur mainly in the cerebellum, can often be cured by surgery. Supratentorial tumours and those arising in the brainstem are much more difficult to resect, and residual or recurrent disease is, therefore, a common event. The latter are treated with radiotherapy or conventional chemotherapy (e.g. SIOP-LGG 2004 protocol). However, both treatments are associated with substantial long-term toxicity, and these tumours frequently evolve into chronic disease with high morbidity [2–6].

The genomic landscape of pLGGs is now being defined. The most frequent genetic alterations are the *KIAA1549-BRAF* fusion gene and the BRAF V600E single point mutation [3]. Other mutations, such as *FGFR1* alterations, are mainly expressed only by specific pLGGs subtypes, such as DNET [7]. Along with the dysregulated MAPK/ERK signalling mentioned above [8–10], aberrant activation of the PI3K/AKT signalling pathway, which can be demonstrated

by high levels of phosphorylated AKT (p-AKT), is also a well-documented feature of gliomas, including pLGGs [3,11,12]. In some cases, its dysregulation has been linked to genetic changes, such as *BRAF* fusions, *FGFR1* duplications and *MYB* rearrangements [3], or epigenetic modifications, but in many cases the mechanism underlying PI3K/AKT pathway activation is still unknown.

MicroRNAs are emerging as major regulators of cancer-related gene expression. In this study, we examined the role of dysregulated microRNA expression in pLGGs, in particular in pLGGs arising in supratentorial areas of the brain, which have the poorest clinical outcomes. Our microRNA profiling analysis of a large series of grade I LGGs from paediatric patients pointed to the PI3K/AKT pathway as one of the most likely 'targets' of dysregulated microRNA expression. In particular, we identified a novel microRNA-mediated mechanism that could be responsible for the hyperactivation of the PI3K/AKT signalling pathway. It involves the markedly down-regulated expression of miR-139-5p, which was observed in the pLGG samples we analysed. Dysregulation of miR-139-5p has been linked to various types of cancer, including adult gliomas and paediatric high-grade gliomas (pHGGs) [13–15], but its role in pLGGs has *not* been investigated yet. Our functional studies in short-term cultures from primary supratentorial pLGGs indicate that the down-regulation of miR-139-5p in these tumours promotes PI3K/AKT pathway activation, thereby enhancing pLGG cell growth.

Materials and methods

Unless otherwise stated, commercially available products were used according to the manufacturer's instructions/protocols.

Tumour samples and controls

microRNA profiling was performed with quantitative PCR (qPCR) (as described below) on RNA extracted from snap-frozen tumour tissue samples from 45 patients (aged 1–16 years) with pLGGs. All underwent surgery at the Bambino Gesù Children's Hospital in Rome or the Gaslini Institute in Genoa between 2014 and 2016. The clinical and pathological features of each case are summarized in Table 1.

RNA and DNA used for the analyses were extracted from tumour samples with pathologist-confirmed tumour cell contents of 80% or more. For control purposes, we profiled eight samples (three + a pool of five) of non-neoplastic brain tissue purchased from Ambion-Life Technology (Thermo Scientific, Wilmington, MA, USA) ($n = 1$: AM7962, Human Brain Total RNA) or Biochain Institute (Newark, CA, USA) ($n = 7$: R1234035-50, Total RNA-Human Adult Normal Tissue-Brain; R1234035-P, Total RNA-Human Adult Normal Tissue-5 Donor Pool-Brain; R1234035-50, Total RNA-Human Adult Normal Tissue-Brain) and 28 samples (four + a pool of 24) of non-neoplastic brain cerebellum purchased from Biochain Institute ($n = 4$: R1234039-50, Total RNA-Human Brain cerebellum) or Clontech Laboratories (Takara Bio USA Inc., Shiga, Japan) ($n = 1$: 636535, Total RNA-Human Brain cerebellum-24 Donor Pool-Brain). MicroRNA profiles for the pLGGs were also compared with profiles previously reported by our group for 13 pGGs, which had been collected between 2005 and 2010 from patients aged from 3 to 17 years [15]. To ensure the comparability of these two cohorts, we reanalysed the microRNA profiles originally reported for the pGGs [15] using the same normalization procedure and statistical methods employed for comparing the pLGGs with healthy brain tissues, as reported below.

For functional studies, we established short-term cultures of pLGG cells isolated from four primary tumours resected at Bambino Gesù Children's Hospital (Rome) in 2016 (Table 2). We deliberately selected tumours with non-PA histology, since the biology of these pLGGs has been much less thoroughly explored than that of PAs. We also limited our analysis to supratentorial pLGGs, which are associated with lower miR-139-5p levels, lower resectability rates and worse outcomes than their infratentorial counterparts [11].

Histology

Formalin-fixed paraffin-embedded (FFPE) samples of each of the 45 pLGGs used in the study were sectioned (3- μ m) and stained with haematoxylin and eosin for histology. All tumour diagnoses were then confirmed by consensus decision of three neuropathologists (F.G., M.A. and F.D.C.) using the WHO classification criteria [1].

Immunohistochemistry

Immunohistochemical studies were performed using anti-PIK3CA (Clinisciences, Nanterre, France), anti-phospho-p70 S6 kinase (Thr389) and anti-phospho-Akt (Ser473) (Cell Signalling Technology, Danvers, MA, USA). Paraffin-embedded slices of supratentorial pLGG tissues derived from the Pathology Department of the Bambino Gesù Children's Hospital in Rome were used for the staining.

For validation of PIK3CA, phosphorylated-p70 S6 kinase (p-p70 S6K) and phospho-AKT (p-AKT) immunohistochemical assay we tested positive tissues. Hepatocellular carcinoma samples were used for PIK3CA and breast cancer samples were used for p-p70 S6K and p-AKT. For negative control primary antibody was omitted. For the evaluation of PIK3CA, p-p70 S6K and p-AKT staining we used a scoring system. We considered: 0 for no staining; 1+ for barely perceptible staining; 2+ for light to moderate staining; and 3+ for moderate to heavy staining.

RNA extraction of pLGG tissues and cells

Please see Appendix S1 for a detailed description.

Analysis of *BRAF* status

Each of the 45 pLGGs and the four patient-derived pLGG cell lines were analysed for the two most common genetic alterations found in these tumours – namely, the *BRAF* V600E point mutation (V600E) and the *KIAA1549:BRAF* fusion gene [including the three most frequent variants: *KIAA1549-BRAF* exon 16-exon 9 (K16B9), *KIAA1549-BRAF* exon 16-exon 11 (K16B11), and *KIAA1549-BRAF* exon 15-exon 9 (K15B9)].

BRAF fusion analysis *BRAF* fusion analysis was performed on tumour cDNAs with the Applied Biosystems Viia7 real-time qPCR (RT-qPCR) System, as

Table 1. Clinical-pathological features of the 45 pLGG cases subjected to microRNA expression profiling

Sample	Age at diagnosis (year)	Gender	Histology	WHO grade	Location	BRAF alterations [†]
P5	3	M	AG	II	Supra	–
P38 [‡]	12.3	M	AG	I	Supra	–
P3 [‡]	9	F	DNET	I	Supra	–
P11	10	F	DNET	I	Supra	–
P16 [‡]	5.8	M	DNET	I	Supra	–
P32	8.4	F	DNET	I	Supra	–
P8	7.6	F	GG	I	Supra	–
P18 [‡]	14.7	F	GG	I	Supra	V600E
P19	4.5	M	GG	I	Infra	V600E
P22	8	F	GG	I	Infra	K16B9
P26	7	F	GG	I	Supra	–
P29	11.3	M	GG	I	Infra	–
P36	5.5	M	GG	I	Infra	K15B9
P41	1.6	M	GG	I	BS	–
P33	9.1	F	GNT	I	Infra	K15B9
PI	15	F	PA	I	Infra	–
P2	1	F	PA	I	Infra	K16B9
P4	12	M	PA	I	Infra	–
P6	9	M	PA	I	Supra	K16B9
P7	6.1	F	PA	I	Infra	K16B9
P9	1.9	F	PA	I	Infra	K15B9
P10	16.2	M	PA	I	Infra	–
P12	3.8	M	PA	I	Infra	K16B9
P13	5.7	M	PA	I	Infra	–
P14	1.3	F	PA	I	Infra	–
P15	10	F	PA	I	Infra	–
P17	12	M	PA	I	Infra	–
P20	4.4	F	PA	I	Infra	K16B9
P21	10	M	PA	I	Supra	–
P23	11	F	PA	I	Infra	–
P24	3	M	PA	I	Supra	K16B9
P25	9.4	F	PA	I	BS	K16B9
P27	10	M	PA	I	Infra	K16B9
P28	7	F	PA	I	BS	–
P30	6.8	F	PA	I	Supra	K16B11
P31	10.2	M	PA	I	Infra	K16B9
P34	5	M	PA	I	Supra	–
P35	7.5	M	PA	I	Infra	K16B9
P37	3.2	M	PA	I	Supra	K15B9
P39	6.6	M	PA	I	Supra	–
P40	1.4	M	PA	I	Infra	K16B9
P42	3.3	M	PA	I	Infra	–
P43	1.8	F	PA	I	Infra	–
P44	3.6	M	PA	I	Supra	K15B9
P45	3.1	M	PA	I	Infra	V600E

AG, angiocentric glioma; BS, brain stem; DNET, dysembryoplastic neuroepithelial tumour; GG, ganglioglioma; GNT, glioneruoal tumour; Infra, infratentorial; PA, pilocytic astrocytoma; pLGG, pediatric low-grade glioma; Supra, supratentorial; –, not detected.

[†]BRAF screening was limited to the V600E point mutation and three gene fusions [KIAA1549-BRAF exon 16-exon 9 (K16B9), KIAA1549-BRAF exon 16-exon 11 (K16B11), KIAA1549-BRAF exon 15-exon 9 (K15B9)].

[‡]Primary pLGG cell lines were derived from these tumours (see Table 2).

described by Tian *et al.* [16] and validated by PCR-based Sanger sequencing through amplification with specific pairs of primers flanking the fusion point between the *KIAA1549* (in exon 15 or 16) and *BRAF*

(in exon 9 or 11) genes, as described by Jones *et al.* [17]. The purified PCR products were sequenced on an ABI 3130 XL DNA analyzer (Applied Biosystems) using the BigDye Terminator v1.1 cycle sequencing kit

Table 2. Clinical-pathological features of patient-derived primary pLGG cell lines

Sample	Parental tumour	Age at diagnosis	Gender	Histology	Location	BRAF alterations [†]	
						Tumour tissue	Isolated cells
pLGG1	P38	12.3	M	AG	Supra	–	–
pLGG2	P3	9	F	DNET	Supra	–	–
pLGG3	P16	5.8	M	DNET	Supra	–	–
pLGG4	P18	14.7	F	GG	Supra	V600E	V600E

AG, angiocentric glioma; DNET, dysembryoplastic neuroepithelial tumour; GG, ganglioglioma; NS, not screened; pLGG, pediatric low-grade glioma; Supra, supratentorial; –, not detected.

[†]BRAF screening was limited to the V600E point mutation and three gene fusions [KIAA1549-BRAF exon 16-exon 9 (K16B9), KIAA1549-BRAF exon 16-exon 11 (K16B11), KIAA1549-BRAF exon 15-exon 9 (K15B9)].

(Applied Biosystems) and the forward or reverse primer used to perform the PCR. The primer sequences were as follows: *KIAA1549* exon 15: 5'-CGG AAA CAC CAG GTC AAC GG-3'; *KIAA1549* exon 16: 5'-AAA CAG CAC CCC TTC CCA GG-3'; *BRAF* exon 9: 5'-CTC CAT CAC CAC GAA ATC CTT G-3'; *BRAF* exon 11: 5'-GTT CCA AAT GAT CCA GAT CCA TTC-3'.

BRAF V600E mutation DNA was extracted from fresh-frozen samples and patient-derived pLGG cell lines using the QIamp DNA mini kit (Qiagen Inc., Valencia, CA, USA). Quantity and quality were evaluated with a Nanodrop ND-1000 spectrophotometer (Thermo Scientific). RT-qPCR was performed, as described by Diniz *et al.* [18], using TaqMan probes (Life Technologies, Waltham, MA, USA): BRAF_476_mu, which detects T>A transversion at position c.1799, and the reference-gene probe BRAF_rf. Threshold cycle (Ct) values were analysed using Mutation Detector™ Software (Life Technologies). Genomic DNA extracted from BRAF V600E and BRAF wild-type colon cancer cell lines, kindly provided by Prof. Matilde Todaro (University of Palermo), were used as positive and negative controls, respectively.

MicroRNA profiling and data analysis

MicroRNA expression profiling was performed on the pLGG tumours using RT-qPCR with Taqman Low Density Array (TLDA) microfluidic cards (Human miR v3.0; Applied Biosystems), which detect the 754 best characterized members of the human microRNA genome. Each reverse transcriptase reaction was performed with specific primers according to Applied Biosystems protocols. The same method had been used to profile the pHGGs in [15].

Statistical analysis was performed with StatMiner™ software, v. 5.0 (Integromics TM, Granada, Spain). MicroRNA expression levels were normalized by using the global expression normalization method and the comparative threshold cycle method was used to calculate the relative microRNA expression. MicroRNAs with C_t values >33 were excluded. Differential expression between groups was assessed with the Limma test, and *P* values <0.05 were considered to be statistically significant.

A single-assay qPCR for assessment of miR-139-5p expression (Code:002289) was carried out in triplicate using the TaqMan Individual microRNA assays (Applied Biosystems), as previously described [15]. Information regarding microRNA clusters was obtained from miRBase v.21 (<http://www.mirbase.org/>) [19]. Validated targets of hsa-miR-139-5p were identified by interrogation of the miRTarBase (<http://mirtarbase.mbc.nctu.edu.tw/>) [20] and literature reports [13,14].

MicroRNAs clustering analysis

Dendrograms and heat maps were generated with the use of R (<http://www.r-project.org/>) using differentially expressed microRNAs as input. The Bray–Curtis method and the average linkage were used in hclust to cluster the samples and heatmap.2 to generate the heat maps [21].

DIANA mirPath analysis

The microRNAs that were differentially expressed in pLGGs (vs. non-neoplastic brain tissue controls) were loaded into the DIANA mirPath tool (<http://snf-515788.vm.okeanos.grnet.gr/>) [22] for microRNA

pathway analysis. MicroRNAs that were significantly dysregulated in the tumours were then analysed to identify their putative targets.

Patient-derived primary pLGG cell cultures

Culture and characterization Human pLGG samples (described above) were collected immediately after resection and placed in Hank's Balanced Salt Solution supplemented with 0.5% glucose and penicillin-streptomycin. The tissues were triturated with a serological pipette. DNase I was added (final concentration 0.04%) and left for 20 min. Cell aggregates were then mechanically disrupted with pipettes of decreasing bore size. The single-cell suspension thus obtained was then centrifuged, and the cells suspended in NHA complete medium (Lonza, Basel, Switzerland), counted and plated at a density of 160 000/ml. Prior to use in experiments, isolated primary pLGG cells underwent quality control assays to ensure they were reliable pLGG models. To this end, we verified that the *BRAF* status of each cell line was identical to that of the parent tumour (as described above in Analysis of *BRAF* status). For the three primary pLGG cells whose primary tumour did not show any genetic alteration on the *BRAF* gene, we compared methylation profiles to verify similarity between the primary cell line and the parental tumour. Immunofluorescence staining (described below) was used to confirm that the cells' histotype-specific glial/neuronal cell biomarker profile was consistent with those described in the literature [23–25]. The percentage of senescent cells was also evaluated by staining for Senescence-associated- β -galactosidase (SA- β -gal, described below). Cultures with SA- β -gal-positivity rates of 60% or more were excluded from experimentation. During the study, cells were discarded after a maximum of eight passages (about 30 days of culture) or when SA- β -gal-positivity rates reached 60%.

Cell treatments Synthetic miR-139-5p (miRIDIAN microRNA code: C-310568-07; Dharmacon, Cornaredo, Milan, Italy) or negative control (miRIDIAN microRNA negative control code: CN-001000-01; Dharmacon) were transfected into pLGG primary cells at 20 nM using HiPerFect transfection reagent (Qiagen Inc.) for 48 h. miR-139-5p overexpression was confirmed by single assay qRT-PCR. For pharmacological inhibition of PI3K, LY294002 was purchased from Sellekchem, dissolved in

DMSO, and stored until used in aliquots at -80°C as 50 mM stock solutions. LY294002 and controls (CTRL) (0.1% DMSO) were diluted in culture medium just before use. After 30 min of treatment with 50 μM LY294002, cells were shifted in normal culture medium for a recovery period of 48 h.

Cell growth was evaluated after 48 h by trypan blue exclusion assay. Specifically, the number of cells that did not take up trypan blue (viable cells) was counted both after transfection of synthetic miR-139-5p or negative control. The number of cells that took up trypan blue (nonviable cells) was counted. Each sample was measured in triplicate and repeated at least three times.

DNA methylation array data generation

DNA methylation profiling using the Illumina Infinium HumanMethylation EPIC BeadChip array was performed according to the manufacturer's instructions at the Genetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, Rome, Italy. In detail 250 ng of DNA was used as input material for fresh-frozen tissue and primary cell line samples (after about 15 days of culture). t-Distributed stochastic neighbor embedding (TSNE) analysis was conducted as previously described [26]. Basic array processing and clustering analysis were performed using Illumina GenomeStudio V2011.1 (Methylation Module version 1.9.0, content descriptor version 1.2) (<https://www.illumina.com/techniques/microarrays/array-data-analysis-experimental-design/genomestudio.html>) (Illumina, Inc., San Diego, CA, USA). Signal intensities were obtained without background subtraction and normalized to internal controls. Beta-values were used for downstream methylation analyses.

Immunofluorescence studies

Please see Appendix S1 for a detailed description.

SA- β -gal activity

SA- β -gal activity was assessed as described in Debacq-Chainiaux [28] with minor modifications. Briefly, cells were fixed with 3.6% of formaldehyde in phosphate buffered saline for 4 min at room temperature. Fixed cells were washed and incubated overnight with freshly

prepared staining solution at 37°C in the absence of CO₂. The cells were washed, and coverslips were mounted in antifade medium (Dako Fluorescence mounting medium; Agilent Technologies, Santa Clara, CA, USA). Images were acquired using a Leica DM2500 microscope (Leica Microsystems, Wetzlar, Germany) with a 20×/0.40 NA objective. Pictures were taken using the ISCapture software and processed with Adobe Photoshop (Mountain View, CA, USA) to adjust brightness and contrast. The percentage of positive cells was evaluated by dividing the number of blue cells on the total number of cells in the field [8].

Western blotting

Please see Appendix S1 for a detailed description.

Statistical analysis

Data reported in this paper are the means ± SD of at least three independent experiments each performed in triplicate. Unpaired *t*-test and paired *t*-test were performed wherever appropriate using GraphPad Prism software version 6.0 (La Jolla, CA, USA), *P* values <0.05 were considered to be statistically significant.

Results

Characteristics of the pLGG cohort

The clinical and pathological features of the 45 primary pLGGs we analysed are summarized in Table 1. Thirty (67%) of the tumours were PAs, eight (18%) were gangliogliomas (GGs), four (9%) were DNETs, two (4%) were AGs and one (2%) was a glioneuronal tumour. Patients' age at diagnosis ranged from 1 to 16 years (median 7 years; mean 7.1 years). Three were located in the brain stem (two PAs, one GG). The other 42 included comparable numbers of infratentorial (*n* = 25) and supratentorial (*n* = 17) tumours. *KIAA1549:BRAF* fusion genes were common, in accordance to literature [3]. The K16B9 variant – the one most frequently encountered – was present in 18 (27%) pLGGs, most of which (13, 52%) were infratentorial. *BRAF* fusions were less common in the supratentorial tumours [5/18 (29%)]. Three pLGGs harboured the *BRAF* V600E point mutation (two infratentorial and one supratentorial).

MicroRNA profiles of pLGGs

We measured the expression levels of 754 microRNAs in the 45 pLGGs described above and compared them with non-neoplastic brain (CTRL). The results were also compared with profiles previously reported by our group for 13 pHGGs (glioblastoma multiforme, *n* = 8; anaplastic astrocytoma, *n* = 5) [15]. The TLDA analysis reported similar high detection rates in all the three tissue groups [474 (63%) of the 754 microRNAs were identified in pLGGs, 436 (58%) in pHGGs and 368 (49%) in CTRL].

The differentially expressed microRNAs (Tables S1 and S2) were plotted using hierarchical clustering, as reported in Figure 1. Some of the most striking alterations involved upregulation of microRNAs with documented oncogenic effects in many tumours (e.g. miR-21 and members of the miR-17-92 cluster) [15,30] or down-regulation of microRNAs with reported oncosuppressive effects in various settings. The latter included miR-218 [31], miR-124 [30], miR-487b [32] and miR-139-5p [33–37].

We further evaluated the microRNAs profiles of supratentorial and infratentorial tumours with respect to non-neoplastic brain or normal cerebellum as CTRL, respectively. Among supratentorial tumours, 69 microRNAs displayed significant tumour-related upregulation (*n* = 28) or down-regulation (*n* = 41) (*P* < 0.05) (Tables 3 and 4). Whereas in the analysis between infratentorial tumours and normal cerebellum 109 microRNAs displayed significant tumour-related up (*n* = 52) or down-regulation (*n* = 57) (*P* < 0.05) (Tables S3 and S4).

Among dysregulated microRNAs, miR-139-5p was noteworthy since it was significantly down-regulated only in supratentorial pLGGs (Table 4) and its down-regulated expression has been documented in high-grade gliomas (adult and paediatric) [13–15], but still unexplored in pLGGs.

Interestingly, the number of differentially expressed microRNAs in pLGGs and pHGGs was lower than that observed when pLGGs were compared with non-neoplastic brain tissues (Tables S5 and S6). The pLGG and pHGG samples segregated into two main clusters (Figure S1). The first (left side of Figure S1) comprised 19 of the 45 pLGGs. The second (right side of Figure S1) was more heterogeneous and contained two subclusters: one contained 21 pLGGs, the second included both




Figure 1. Hierarchical clustering of microRNAs displaying differential expression in paediatric low-grade gliomas (pLGGs) vs. non-neoplastic brain tissues (controls, CTRL). Hierarchical clustering of the 93 microRNAs differentially expressed in pLGGs vs. CTRL ($P < 0.05$) was performed and the Euclidean method was used to generate clusters on the basis of delta Ct values. Tissue: PA, pilocytic astrocytoma (blue); GG, ganglioglioma (red); GNT, glioneuronal tumour (purple); DNET, dysembryoplastic neuroepithelial tumour (orange); AG, angiocentric glioma (light blue). BRAF status was defined exclusively by the presence/absence of the V600E point mutation (green) and KIAA1549-BRAF fusion variants (yellow) (KIAA1549-BRAF exon 16-exon 9, KIAA1549-BRAF exon 16-exon 11, or KIAA1549-BRAF exon 15-exon 9). NEG, negative for all analysed mutations (black).

Table 3. MicroRNAs displaying significantly upregulated expression in supratentorial pLGGs with respect to non-neoplastic brain tissues (CTRL)

microRNA	LFC	P-value	Part of cluster	Chr
hsa-miR-663b	46.20	3.99E-03		
hsa-miR-193a-3p	45.40	4.06E-02		
hsa-miR-378	31.89	1.60E-02		
hsa-miR-576-3p	17.65	2.46E-02		
hsa-miR-1275	17.02	2.57E-02		
hsa-miR-1225-3p	15.70	1.84E-02		
hsa-miR-337-5p	11.84	4.34E-02	493-136	chr 14
hsa-miR-550a-3p	11.32	2.16E-03	550a~550b	chr7
hsa-miR-483-5p	10.93	1.05E-02		
hsa-miR-18a-5p	10.34	1.20E-02	17~92a-1	chr 13
hsa-miR-720	9.61	3.38E-04		
hsa-miR-1233-3p	9.47	2.63E-02		
hsa-miR-106b-3p	6.43	3.29E-03	106b~25	chr7
hsa-miR-296-5p	6.05	4.68E-03	298-296	chr20
hsa-miR-29a-5p	5.96	4.09E-02	29b-1~29a	chr7
hsa-miR-661	5.95	9.16E-03		
hsa-miR-9-3p	5.53	9.78E-04		
hsa-miR-1260a	5.21	5.65E-04		
hsa-miR-301a-3p	5.15	8.52E-04		
hsa-miR-497-5p	4.69	9.94E-05	497-195	chr 17
hsa-miR-99a-3p	3.88	3.27E-03	99a-let-7c	chr21
hsa-miR-455-5p	3.85	2.14E-02		
hsa-miR-34a-3p	3.42	2.33E-02		
hsa-miR-27a-3p	2.97	1.98E-02	23a~24-2	chr 19
hsa-miR-19a-3p	2.81	0.0423	17~92a-1 44329	chr 13
hsa-miR-362-5p	2.34	3.19E-02	532-502	chrX
hsa-miR-193 a-5p	2.32	4.57E-02		
hsa-miR-181a-2-3p	2.14	3.68E-02	181a-2~ 181b-2	chr9

LFC, linear fold change; Chr, chromosome.

pLGGs and pHGGs. This finding highlighted the existence of a gradient of microRNA expression reflecting internal variation within the pLGGs cohort. Notably, the expression levels of miR-139-5p in pLGGs resembled those found in pHGGs.

PI3K/AKT signalling is controlled by microRNAs that are dysregulated in pLGGs

To explore the functional implications of the microRNA profile of our pLGGs cohort, we used the DIANA miR-Path tool to identify signalling pathways likely to be vulnerable to the altered microRNA expression levels found in these tumours. As summarized in Table 5, after the broader category pathways in cancer, the PI3K/AKT pathway contained the highest number of

Table 4. MicroRNAs displaying significantly down-regulated expression in supratentorial pLGGs with respect to non-neoplastic brain tissues (CTRL)

microRNA	LFC	P-value	Part of cluster	Chr
hsa-miR-147b	0.006	7.85E-03		
hsa-miR-512-3p	0.007	1.93E-02	512-l~519a-2	chr 19
hsa-miR-657	0.009	4.90E-02	1250-657	chr 17
hsa-miR-523-3p	0.016	4.90E-02	512-l~519a-2	chr 19
hsa-miR-485-5p	0.017	2.82E-03	379-656	chr 14
hsa-miR-138-2-3p	0.017	8.82E-03		
hsa-miR-187-3p	0.024	2.58E-02		
hsa-miR-522-3p	0.044	3.44E-02	512-l~519a-2	chr 19
hsa-miR-425-3p	0.044	1.17E-02	191-425	chr3
hsa-miR-423-5p	0.048	3.08E-03	423-3184	chr 17
hsa-miR-577	0.083	2.72E-02		
hsa-miR-889-3p	0.100	4.60E-02	379-656	chr 14
hsa-miR-184	0.108	3.24E-02		
hsa-miR-128-3p	0.114	2.69E-02		
hsa-miR-133a-3p	0.144	9.51E-03	1-2~133a-1	chr18
hsa-miR-139-5p	0.147	3.68E-02		
hsa-miR-203a	0.153	2.05E-02	203a~203b	chr 14
hsa-miR-31-5p	0.156	3.28E-02		
hsa-miR-23b-3p	0.168	4.04E-02	23b~24-1	chr9
hsa-miR-654-5p	0.172	2.18E-02		
hsa-miR-495-3p	0.184	1.07E-02	379-656	chr 14
hsa-miR-539-5p	0.198	5.34E-03	379-656	chr 14
hsa-miR-149-5p	0.200	3.98E-02		
hsa-miR-138-5p	0.205	2.60E-02		
hsa-miR-7-l-3p	0.215	3.27E-02		
hsa-miR-487b-3p	0.215	1.56E-02	379-656	chr 14
hsa-miR-625-5p	0.226	3.35E-02		
hsa-miR-132-3p	0.252	1.18E-02	212-132	chr 17
hsa-miR-330-3p	0.266	0.0110	63144	
hsa-miR-628-5p	0.270	8.66E-03		
hsa-miR-323a-3p	0.270	3.29E-02	379-656	chr 14
hsa-miR-410-3p	0.276	2.29E-02	379-656	chr 14
hsa-miR-491-5p	0.277	7.67E-03		
hsa-miR-95-3p	0.332	3.67E-02		
hsa-miR-379-5p	0.345	1.59E-02	379-656	chr 14
hsa-miR-342-3p	0.350	2.66E-02	342~151b	chr 14
hsa-miR-200c-3p	0.362	3.55E-02	200c-141	chr 12
hsa-miR-411-5p	0.412	0.0240	379-656	chr 14
		12639		
hsa-miR-126-3p	0.418	3.91E-02		
hsa-miR-103a-3p	0.450	3.53E-02		
hsa-miR-191-5p	0.493	3.44E-02	191-425	chr3

LFC, linear fold change; Chr, chromosome.

components putatively targeted by the microRNAs dysregulated in our pLGG cohort. This finding is consistent with recent reports of aberrant PI3K/AKT/mTOR signalling in paediatric gliomas, both high- and low-grade [11,12]. This hyperactivation has been attributed to genetic and epigenetic alterations in certain glioma

Table 5. The 20 most markedly enriched biological processes using up- or down-regulated microRNAs in pLGGs

KEGG pathway	P-value	#genes	#microRNAs
Up regulated microRNAs in pLGG vs. CTRLs			
Proteoglycans in cancer	3.31E-10	144	62
Signalling pathways regulating pluripotency of stem cells	1.19E-07	104	65
Pathways in cancer	8.43E-06	263	63
Wnt signalling pathway	1.68E-05	100	61
Rapl signalling pathway	1.50E-04	144	63
Ras signalling pathway	3.51E-04	151	62
PI3K-Akt signalling pathway	4.91E-04	223	66
Focal adhesion	4.91E-04	141	64
Regulation of actin cytoskeleton	3.10E-03	142	62
MAPK signalling pathway	9.55E-03	163	62
Down regulated microRNAs in pLGG vs. CTRLs			
Hippo signalling pathway	3.78E-09	114	53
Pathways in cancer	5.31E-08	278	58
Axon guidance	1.77E-07	100	53
Proteoglycans in cancer	1.82E-07	142	55
Rapl signalling pathway	6.52E-05	148	53
PI3K-Akt signalling pathway	6.29E-04	226	53
Oxytocin signalling pathway	1.98E-03	109	53
Ras signalling pathway	1.68E-02	146	54
Regulation of actin cytoskeleton	1.97E-02	141	54
HTLV-I infection	3.07E-02	167	55

Processes were identified and ranked according to P-value, as assigned in KEGG pathway analysis using DIANA-miRPath (v. 3.0).

subsets, but in many cases the cause is still unknown. We noted with interest, therefore, that *PIK3CA*, which encodes the catalytic subunit of phosphatidylinositol 3-kinase (PI3K), is a validated target of miR-139-5p, as demonstrated by luciferase assay in Krishnan *et al.* [38]. The marked dysregulation of this tumour-suppressor microRNA in pLGGs was documented for the first time in our cohort (Tables S2 and 4).

Down-regulation of miR-139-5p in pLGGs favours tumour-cell proliferation

Taken together, these findings suggested that down-regulation of miR-139-5p in supratentorial tumours might contribute to the development of pLGGs by derepressing expression of *PIK3CA*, thereby favouring aberrant activation of the PI3K/AKT pathway. To address this hypothesis, we firstly investigated the expression of *PIK3CA* by performing immunohistochemistry assay in pLGG tissues derived from AG, DNET and GG tumours, which are predominantly supratentorial. As reported in Figure S2, pLGGs showed positive staining for *PIK3CA*, with an average of 25% positive cells and a 2+/3+ score. Then, we carried out *in vitro* experiments in

primary monolayer cultures of pLGG cells isolated from patient-derived samples of AG, DNET and GG. The characteristics of these cells are summarized in Table 2 and their growth curves and description are reported in greater detail in Figures 2, 3, S3 and S4. The immunofluorescence staining confirmed the glial and/or mixed neuro-glial nature of the primary pLGG cells. For all the histological types, cells were positive for the glial markers vimentin and S100, while the level of glial fibrillary acidic protein positivity was more variable ranging from 20% to 70%. In DNET and GG samples, we also detected frequent positivity for NeuN and Synaptophysin, neuronal markers, which conversely were absent in the AG. Therefore, the immunofluorescence staining together with the methylation profiling, a method to evaluate the similarity among tumours samples and their derived primary cells [10,26,39–41], indicate that our primary cells are a suitable and trustworthy model to study supratentorial pLGGs biology.

MiR-139-5p levels in supratentorial pLGGs were markedly lower than those in non-neoplastic total brain tissues (Table 4, Figure 4a). Down-regulation of miR-139-5p was also evident in our patient-derived primary pLGG cell cultures at levels comparable to




Figure 2. Immunofluorescence characterization of primary patient-derived pLGG cells. (a–c) Single-cell monolayers (on the average present after 7 days of culture) were subjected to immunofluorescence staining for glial markers (S100, vimentin, glial fibrillary acidic protein) and neuronal markers (NeuN, synaptophysin). In detail, (a) AG-derived cells (pLGG1) show positivity for glial markers only [23], whereas (b) DNET-derived cells (findings shown for pLGG2 are also representative of DNET line pLGG3) [24] and (c) GG-derived cells (pLGG4) expressed both glial and neuronal markers [25]. The positivity and negativity of the staining of the observed glial and neuronal markers was concordant with immunohistochemical staining results obtained by pathologists on formalin-fixed paraffin-embedded samples of the tumours from which pLGG lines 1, 2 and 4 were derived (data not shown). Scale bars, 50 and 100 μ m (high magnification insert). AG, angiocentric glioma; pLGG, paediatric low-grade gliomas; GG, ganglioglioma; DNET, dysembryoplastic neuroepithelial tumour.

those of the primary tumours they derive from (Figure 4b). Overexpression of miR-139-5p in these cells (Figure S5) resulted in significantly reduced proliferation, which was evident in all three histological types represented (Figure 4c–f), while not affecting cell death (data not shown).

miR-139-5p controls PI3K/AKT/mTORC1 signalling in supratentorial pLGGs

The results of the previous experiments provide evidence that down-regulation of miR-139-5p plays a role in supratentorial pLGG cell growth. To determine whether its effects on cell growth were mediated by derepressed PI3K activity, we assessed the effects of miR-139-5p overexpression on the phosphorylation of the PI3K target, AKT. At baseline, p-AKT levels were high in all the cell cultures tested, but they dropped

markedly after miR-139-5p overexpression (Figure 5a–c). In order to investigate whether miR-139-5p effect was directly mediated by PI3K inhibition, we examined proliferation and p-AKT levels in primary pLGG cells before and after treatment with the direct PI3K inhibitor LY294002. Our results showed that LY294002 treatment caused a significant impairment of cell proliferation (Figure 5d–g) and decreased levels of p-AKT (Figure 5h–j). Again, we did not observe any significant effect on cell death (data not shown).

One of the downstream effectors of PI3K/AKT signalling is mammalian target of rapamycin complex 1 (mTORC1). Activation of this complex has already been reported in pLGGs [11], and hyperactivation of the PI3K/AKT/mTORC1 axis has been implicated in the increased cell proliferation of these tumours [12]. We therefore wondered if mTORC1 inhibition was involved in the antiproliferative effects produced in pLGG cells




Figure 3. Methylation analysis of primary patient-derived pLGG cells confirms their identity. DNA methylation profiling was performed on the three tumours (an AG and two DNETs) that did not show any genetic BRAF alterations and their primary pLGG derived cells. TSNE (t-distributed stochastic neighbor embedding) analysis of the whole genome DNA methylation data show a close similarity between patient-derived pLGG cell lines, their primary tissues and the group of pLGGs they derive from (AG and DNET) but they diverge from other paediatric low-grade tumours and non-neoplastic cortex. pLGG1, AG tissue and patient-derived cells; pLGG2 and pLGG3, DNET tissues and their respective patient-derived cells (see Table 2). Colour legend of the TSNE plot as follows: PXA (brown); GG (orange); Cortex (light blue); AG (black); PA GG hemispheric (light purple); PA Infratentorial (purple); DNET (blue); PA midline (yellow). PLGG, paediatric low-grade gliomas; AG, angiocentric glioma; DNET, dysembryoplastic neuroepithelial tumour; GG, ganglioglioma; PA, pilocytic astrocytoma; PXA, pleomorphic xanthoastrocytoma.

by miR-139-5p overexpression. As shown in Figure 6a–c, cells transfected with miR-139-5p displayed significantly decreased p-p70 S6K, a hallmark of mTORC1 activation. A comparable reduction was produced when PI3K was inhibited with LY294002 (Figure 6d–f). Furthermore, immunohistochemical staining for p-p70 S6K and p-AKT were performed in pLGG samples. As reported in Figures S6 and S7, tumours showed p-p70 S6K and p-AKT positive staining with an average of more than 10% positive cells and a score 2+ for both assay. Taken together, these data indicate

that the down-regulated expression of miR-139-5p in primary supratentorial pLGG cells increases their proliferation by derepressing PI3K/AKT signalling and that its effect is mediated by mTORC1, as summarized in Figure 7.

Discussion

MicroRNAs have been identified as pivotal players in a variety of cancers [42,43]. Thus far, however, the research conducted on these noncoding RNA species in




Figure 4. Down-regulation of miR-139-5p in pLGGs favours tumour cell-proliferation. (a and b) Single assay qPCR validation of down-regulated miR-139-5p expression in (a) supratentorial pLGG tissues and (b) patient-derived primary pLGG cell lines and their corresponding tissues vs. non-neoplastic total brain tissue (controls, CTRL) (c–f) Effects on cell proliferation of miR-139-5p overexpression in cultured cells from (c) primary AG, (d) primary DNET indicated as pLGG2, (e) primary DNET indicated as pLGG3 and (f) primary GG. Cells were transfected with 20 nM miR-139-5p or an empty vector (CTRL) and subjected to trypan blue staining 48 h later. Relative cell growth refers to fold over CTRL. * $P < 0.05$, ** $P < 0.001$ vs. CTRL. PLGG, paediatric low-grade gliomas; AG, angiocentric glioma; DNET, dysembryoplastic neuroepithelial tumour; GG, ganglioglioma.

pLGGs has been largely descriptive. Moreover, the conclusions that can be drawn from these studies are frequently limited by the small number of cases analysed [31,44], the inclusion of high-grade gliomas besides pLGGs [45,46] or the inclusion of adult patients [32].

Our study differs from its predecessors in several respects. Our microRNA profiling study was conducted on fresh-frozen samples of 45 pLGGs, all of which were grade I tumours resected from patients 16 years of age or younger. We identified 93 microRNAs whose differential expression distinguished the pLGGs from controls. Since a number of microRNAs display directional and quantitative similar dysregulation in pHGG, these microRNAs are more likely to play a role in paediatric gliomas in general than in specific WHO classes of pLGGs. In fact, the down-regulated expression of miR-487b, miR-323a-3p and miR-410 – all members of the 379-656 cluster – has already been described in gliomas of various grades [32,47,48]. Likewise, upregulated expression of miR-18a-5p and miR-20a-5p (both belonging to the miR 17-92 cluster) and of miR-21-5p has been found in pLGGs [32] and pHGGs [15,49,50], as well as in other types of brain tumours [51–53]. Thanks to the results of this first part of the study we were able to identify specific microRNA profiles

for pLGGs that will be object of future experimental investigations.

The importance of the PI3K/AKT/mTOR pathway that emerged from our microRNA pathway analysis was not surprising. Along with the MAPK/ERK axis, it is one of the pathways most frequently upregulated in cancers, including pLGGs [2,3,54,55]. Aberrant activation of PI3K/AKT/mTOR signalling in pLGGs has been reported in association with several genetic alterations, including *BRAF* fusions, *FGFR1* duplications, and *MYB* rearrangements [3], which are present at different frequencies in the various pLGGs histologies, with the last two genetic alterations that have been more specifically detected in DNET and AG, respectively. Epigenetic mechanisms have been investigated as alternative activators of PI3K signalling in these tumours. For instance, promoter methylation and consequent silencing of expression of the gene encoding phosphatase and tensin homolog (*PTEN*) – a major negative regulator of PI3K signalling – has also been documented in some gliomas, and its frequency correlated positively with tumour grading [11,56]. Therefore, *PTEN* promoter methylation, too, is unlikely to account for the oncogenic activation of the PI3K/AKT signalling in most grade I pLGGs.




Figure 5. PI3K/AKT signalling pathway inhibition decreases pLGG AKT phosphorylation and cell proliferation. (a–c) Phosphorylated AKT (p-AKT) and total AKT levels were measured in supratentorial primary pLGG cells transfected with miR-139-5p or empty vector (controls, CTRL) (d–g) AG (d) pLGG2 (DNET) (e) pLGG3 (DNET) (f) and GG (g) cells were treated for 30 min with 50 μ M LY294002 and assayed for proliferation (Trypan blue exclusion) after a 48 h recovery period in normal medium. (h–j) p-AKT and total AKT levels were measured in supratentorial primary pLGG cells treated with 50 μ M LY294002 for 30 min or vehicle alone (CTRL) after a 48 h recovery period in normal medium. Relative cell growth refers to fold over CTRL. * $P < 0.05$, ** $P < 0.001$ vs. CTRL. pLGG, paediatric low-grade gliomas. DNET, dysembryoplastic neuroepithelial tumour.

These considerations heightened our interest in the marked down-regulation of miR-139-5p, which was found in all examined grade I pLGGs. This microRNA has been demonstrated to be a validated negative regulator of the *PIK3CA* gene, which encodes the catalytic subunit of the PI3K [38]. The oncosuppressive effects of miR-139-5p have been described in a variety of solid tumours [37,38,57–59], including adult high-grade gliomas [13,14]. Nonetheless, neither the level of expression of miR-139-5p or its biological role has never been explicitly investigated in pLGGs.

Our functional characterization of miR-139-5p loss in grade I pLGGs provides the first evidence that this alteration may be a key driver of oncogenic activation of the PI3K/AKT/mTORC1 pathway in these tumours. As

illustrated in Figure 7 the down-regulated miR-139-5p expression in supratentorial pLGGs significantly enhances activation of PI3K/AKT/mTORC1 signalling, as reflected by the high phosphorylation levels of AKT and p70 S6K, which dropped markedly after miR-139-5p overexpression, and the biological outcome is a substantial increase in tumour-cell proliferation. MiR-139-5p down-regulation could conceivably act alone to activate this pathway. However, there is no reason to exclude the possibility of additive effects in the presence of the genetic and/or epigenetic mechanisms of activation discussed above. It is also important to recall that miR-139-5p down-regulation might produce additional tumour-promoting effects by depressing other targets, which include numerous genes with documented oncogenic effects in gliomas and in




Figure 6. Phosphorylation of phosphorylated-p70 S6 kinase (p-p70 S6K) in pLGG cells subjected to miR-139-5p overexpression or LY294002 treatment. The overexpression of miR-139-5p (a–c) and direct PI3K inhibition for 30 min with 50 μ M LY294002 followed by a 48 h recovery period in normal medium (d–f) both strongly reduced p70 S6K phosphorylated levels (p-p70 S6K) while leaving unaffected the level of total p70 S6K.

other cancers as well (e.g. FOS, HRAS, JUN, MCL1, NOTCH1, ELTD1, ZEB1 and ZEB2) [13,14,38,57,59–61].

These conclusions are based on the results of studies on the restored expression of miR-139-5p in primary cultures of patient-derived supratentorial pLGG cells, whereas the few functional studies conducted in this area have utilized immortalized pLGG cells, such as the PA-derived Res186 line and/or Res259 cells, originally derived from a grade II diffuse astrocytoma [12,62–64]. A major drawback of these cell lines is that they harbour genetic alterations that are relatively rare in pLGGs, and it is unclear to what extent they represent the primary lesions [12,65, 66]. Previous attempts to use short-term primary cultures of patient-derived pLGGs have been hampered by markedly reduced growth secondary to oncogene induced senescence [8–10]. Protocol differences might contribute to explain why our efforts were more successful. It is worth noting, however, that the unsuccessful attempts cited above all involved the use of cells isolated from PAs, whereas the cells we used came from non-PA pLGGs. This choice was based on our purpose to elucidate the biology of pLGGs arising in supratentorial structures of

the brain, where PAs are less common. Interestingly, however, we also encountered slow growth and senescence in our non-PA cultures (Figure S3a–c). Senescence rates varied widely (even between cultures of cells representing the same pLGG histotype, data not shown), and they generally – but not always – increased over time. For instance, in some cultures, high rates were already observed after the first few passages. By carefully selecting the cultures destined for experiments particularly by analysing their whole genome methylation profile (Figure S4), demonstrated to be a reliable method to pinpoint the identity of a broad range of brain tumours [10,26,39–41], but also continuously monitoring their senescence rates over time, we were able to complete short-term experiments and our assessment of these cells indicates that they are likely to provide reliable representations of the pLGGs seen in the clinic. Therefore, our primary patient-derived pLGG cells present many benefits in comparison with the few immortalized cell lines that have been used until now and represent a more reliable model to study the biology of these tumours, that otherwise would be hardly addressed. The major disadvantage of these cultures is




Figure 7. Down-regulation of miR-139-5p expression in pLGGs promotes proliferation by derepressing PI3K/AKT/mTORC1 signalling. miR-139-5p, that targets the 3'-UTR of *PIK3CA*, is strongly down-regulated in pLGG tumours resulting in the hyper-activation of the PI3K/AKT pathway. After miR-139-5p overexpression in pLGG primary cells both AKT and phosphorylated-p70 S6 kinase (p-p70 S6K) phosphorylation levels are reduced, with a consistent significant impairment in cell proliferation. PTEN, phosphatase and tensin homolog; PI3K, phosphatidylinositol-3-kinase; PDK-1, phosphoinositide-dependent kinase 1; TSC2, tuberous sclerosis complex 2; Rheb, Ras homolog enriched in brain; mTORC1, mammalian target of rapamycin 1; p70 S6K, p70 S6 kinase.

that they represent short-term cultures with a low proliferation rate and the number of experiments that can be performed is limited. Consequently, these primary models can be used only to answer to specific and well-defined biological questions. Interestingly, the methylation profiling allowed us to note that short-term primary cells could be more or less closer to their primary tumour, probably reflecting the heterogeneity of the cellular composition of the primary pLGG tumours analysed.

Since morbidity and mortality, particularly due to disease progression, represent a significant problem in children affected by pLGGs even after many years from diagnosis [5,6,67] there is an urgent need for the identification and use of less toxic therapies, such as molecular targeted agents, in children with LGGs [67]. In

this context, our primary patients'-derived cellular models represent a proper and trustable *in-vitro* model to test molecular targeted compounds.

In summary, the identification of miR-139-5p as a major regulator of the PI3K/AKT/mTORC1 axis in supratentorial pLGGs and the establishment of patients'-derived cellular models represent an important advancement and will open new perspectives to deepen the current knowledge on pLGGs biology.

Acknowledgements

The work was partially supported by Italian Ministry for Instruction, University and Research (to E. Ferretti), University La Sapienza Research Grants (to E. Ferretti), Italian Ministry of Health (to F. Locatelli), Ricerca

corrente Bambino Gesù Children's Hospital (to E. Miele), Associazione EAL Onlus (to A. Mastronuzzi). We thank the Associazione Italiana per la Ricerca dei Tumori Cerebrali del Bambino (ARTUCEBA) of which S. Mascelli and A. Raso are fellows. We thank L. Moi for the technical support and M. Everett Kent for providing writing support.

Author contributions

G.C., E.F., E.M., A.P. conceived and designed research; G.C., Z.M.B., M.C., M.A., M.B., D.S., D.S., D.C. performed research; E.F., M.T., A.v.D., F.G., A.M., F.L. contributed reagents/analytic tools; G.C., Z.M.B., A.P., A.C., C.E.M., A.R., S.M. acquired and analysed data; G.C. and E.F. drafted the manuscript; all co-authors contributed to the final version of the manuscript.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants for whom identifying information is included in this article and that the manuscript does not contain any directly identifiable data.

Conflict of interest

The authors declare that they have no conflict of interest.

References

- Louis DN, Perry A, Reifenberger G, Von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. *Acta Neuropathol* 2016; **131**: 803–20
- Pfister S, Witt O. Pediatric gliomas. In *Gliomas*. Ed. A von Deimling. Berlin; Heidelberg: Springer, 2009; 67–81.
- Zhang J, Wu G, Miller CP, Tatevossian RG, Dalton JD, Tang B, Orisme W, Punchihewa C, Parker M, Qaddoumi I, Boop FA. Project SJsRHWUPCG. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. *Nat Genet* 2013; **45**: 602–12
- Packer RJ, Pfister S, Bouffet E, Avery R, Bandopadhyay P, Bornhorst M, Bowers DC, Ellison D, Fangusaro J, Foreman N. Pediatric low-grade gliomas: implications of the biologic era. *Neuro-Oncology* 2016; **19**: 750–61
- Garcia MA, Solomon DA, Haas-Kogan DA. Exploiting molecular biology for diagnosis and targeted management of pediatric low-grade gliomas. *Future Oncol* 2016; **12**: 1493–506
- Sturm D, Pfister SM, Jones DT. Pediatric gliomas: current concepts on diagnosis, biology, and clinical management. *J Clin Oncol* 2017; **35**: 2370–7
- Qaddoumi I, Orisme W, Wen J, Santiago T, Gupta K, Dalton JD, Tang B, Hauptfear K, Punchihewa C, Easton J. Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. *Acta Neuropathol* 2016; **131**: 833–45
- Jacob K, Quang-Khuong D-A, Jones DT, Witt H, Lambert S, Albrecht S, Witt O, Vezina C, Shirinian M, Faury D. Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas. *Clin Cancer Res* 2011; **17**: 4650–60
- Raabe EH, Lim KS, Kim JM, Meeker A, Mao X-G, Nikkhah G, Maciaczyk J, Kahlert U, Jain D, Bar E. BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model. *Clin Cancer Res* 2011; **17**: 3590–9.
- Selt F, Hohloch J, Hielscher T, Sahm F, Capper D, Korshunov A, Usta D, Brabetz S, Ridinger J, Ecker J. Establishment and application of a novel patient-derived KIAA1549: BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing. *Oncotarget* 2017; **8**: 11460
- Mueller S, Phillips J, Onar-Thomas A, Romero E, Zheng S, Wiencke JK, McBride SM, Cowdrey C, Prados MD, Weiss WA. PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome. *Neuro-Oncology* 2012; **14**: 1146–52
- Hütt-Cabezas M, Karajannis MA, Zagzag D, Shah S, Horkayne-Szakaly I, Rushing EJ, Cameron JD, Jain D, Eberhart CG, Raabe EH. Activation of mTORC1/mTORC2 signaling in pediatric low-grade glioma and pilocytic astrocytoma reveals mTOR as a therapeutic target. *Neuro-Oncology* 2013; **15**: 1604–14
- Dai S, Wang X, Li X, Cao Y. MicroRNA-139-5p acts as a tumor suppressor by targeting ELTD1 and regulating cell cycle in glioblastoma multiforme. *Biochem Biophys Res Comm* 2015; **467**: 204–10

- 14 Yue S, Wang L, Zhang H, Min Y, Lou Y, Sun H, Jiang Y, Zhang W, Liang A, Guo Y. miR-139-5p suppresses cancer cell migration and invasion through targeting ZEB1 and ZEB2 in GBM. *Tumor Biol* 2015; **36**: 6741–9
- 15 Miele E, Buttarelli FR, Arcella A, Begalli F, Garg N, Silvano M, Po A, Baldi C, Carissimo G, Antonelli M. High-throughput microRNA profiling of pediatric high-grade gliomas. *Neuro-Oncology* 2013; **16**: 228–40
- 16 Tian Y, Rich BE, Vena N, Craig JM, MacConaill LE, Rajaram V, Goldman S, Taha H, Mahmoud M, Ozek M. Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. *J Mol Diagn* 2011; **13**: 669–77
- 17 Jones DT, Kocialkowski S, Liu L, Pearson DM, Bäcklund LM, Ichimura K, Collins VP. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. *Can Res* 2008; **68**: 8673–7
- 18 Diniz JG, Gomes CC, Guimarães BVA, Castro WH, Lacerda JCT, Cardoso SV, de Faria PR, Dias FL, Eisenberg ALA, Loyola AM. Assessment of BRAFV600E and SMOF412E mutations in epithelial odontogenic tumours. *Tumor Biol* 2015; **36**: 5649–53
- 19 Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools for microRNA genomics. *Nucleic Acids Res* 2007; **36**: D154–8
- 20 Chou C-H, Chang N-W, Shrestha S, Hsu S-D, Lin Y-L, Lee W-H, Yang C-D, Hong H-C, Wei T-Y, Tu S-J. miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database. *Nucleic Acids Res* 2015; **44**: D239–47
- 21 Suzuki R, Shimodaira H. PvcLust: an R package for assessing the uncertainty in hierarchical clustering. *Bioinformatics* 2006; **22**: 1540–2
- 22 Vlachos IS, Zagganas K, Paraskevopoulou MD, Georgakilas G, Karagkouni D, Vergoulis T, Dalamagas T, Hatzigeorgiou AG. DIANA-miRPath v3.0: deciphering microRNA function with experimental support. *Nucleic Acids Res* 2015; **43**: W460–6
- 23 Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. *Acta Neuropathol* 2007; **114**: 97–109
- 24 Suh Y-L. Dysembryoplastic neuroepithelial tumors. *J Pathol Transl Med* 2015; **49**: 438
- 25 Luyken C, Blümcke I, Fimmers R, Urbach H, Wiestler OD, Schramm J. Supratentorial gangliogliomas: histopathologic grading and tumor recurrence in 184 patients with a median follow-up of 8 years. *Cancer* 2004; **101**: 146–55
- 26 Sturm D, Orr BA, Toprak UH, Hovestadt V, Jones DT, Capper D, Sill M, Buchhalter I, Northcott PA, Leis I. New brain tumor entities emerge from molecular classification of CNS-PNETs. *Cell* 2016; **164**: 1060–72
- 27 Ronci M, Catanzaro G, Pieroni L, Po A, Besharat ZM, Greco V, Levi Mortera S, Screpanti I, Ferretti E, Urbani A. Proteomic analysis of human sonic hedgehog (SHH) medulloblastoma stem-like cells. *Mol BioSyst* 2015; **19**(11): 1603–11
- 28 Debacq-Chainiaux F, Erusalimsky JD, Campisi J, Toussaint O. Protocols to detect senescence-associated beta-galactosidase (SA-βgal) activity, a biomarker of senescent cells in culture and in vivo. *Nat Protoc* 2009; **4**: 1798–806
- 29 Po A, Silvano M, Miele E, Capalbo C, Eramo A, Salvat IV, Todaro M, Besharat Z, Catanzaro G, Cucchi D, Coni S, Di Marcotullio L, Canettieri G, Vacca A, Stassi G, De Smaele E, Tartaglia M, Screpanti I, De Maria R, Ferretti E. Noncanonical GLI1 signalling promotes stemness features and in-vivo growth in lung adenocarcinoma. *Oncogene* 2017; **36**: 4641–4652
- 30 Ho C-Y, Bar E, Giannini C, Marchionni L, Karajannis MA, Zagzag D, Gutmann DH, Eberhart CG, Rodriguez FJ. MicroRNA profiling in pediatric pilocytic astrocytoma reveals biologically relevant targets, including PBX3, NFIB, and METAP2. *Neuro-Oncology* 2012; **15**: 69–82
- 31 Liu F, Xiong Y, Zhao Y, Tao L, Zhang Z, Zhang H, Liu Y, Feng G, Li B, He L. Identification of aberrant microRNA expression pattern in pediatric gliomas by microarray. *Diagn Pathol* 2013; **8**: 158
- 32 Ames HM, Yuan M, Vizcaíno MA, Yu W, Rodriguez FJ. MicroRNA profiling of low-grade glial and glioneuronal tumors shows an independent role for cluster 14q32.31 member miR-487b. *Mod Pathol* 2017; **30**: 204–16
- 33 Bao W, Fu HJ, Xie QS, Wang L, Zhang R, Guo ZY, Zhao J, Meng YL, Ren XL, Wang T. HER2 interacts with CD44 to up-regulate CXCR4 via epigenetic silencing of microRNA-139 in gastric cancer cells. *Gastroenterology* 2011; **141**: 2076–87. e6
- 34 Guo H, Hu X, Ge S, Qian G, Zhang J. Regulation of RAP1B by miR-139 suppresses human colorectal carcinoma cell proliferation. *Int J Biochem Cell Biol* 2012; **44**: 1465–72
- 35 Wong CCL, Wong CM, Tung EKK, Au SLK, Lee JMF, Poon RTP, Man K, Ng IOL. The microRNA miR-139 suppresses metastasis and progression of hepatocellular carcinoma by down-regulating Rho-kinase 2. *Gastroenterology* 2011; **140**: 322–31
- 36 Mao R, Zou F, Yang L, Lin S, Li Y, Ma M, Yin P, Liang X, Liu J. The loss of MiR-139-5p promotes colitis-associated tumorigenesis by mediating PI3K/AKT/Wnt signaling. *Int J Biochem Cell Biol* 2015; **69**: 153–61
- 37 Qiu G, Lin Y, Zhang H, Wu D. miR-139-5p inhibits epithelial–mesenchymal transition, migration and invasion of hepatocellular carcinoma cells by targeting ZEB1 and ZEB2. *Biochem Biophys Res Comm* 2015; **463**: 315–21
- 38 Krishnan K, Steptoe AL, Martin HC, Pattabiraman DR, Nones K, Waddell N, Mariasegaram M, Simpson PT,

- Lakhani SR, Vlassov A. miR-139-5p is a regulator of metastatic pathways in breast cancer. *RNA* 2013; **19**: 1767–80
- 39 Lambert SR, Witt H, Hovestadt V, Zucknick M, Kool M, Pearson DM, Korshunov A, Ryzhova M, Ichimura K, Jabado N. Differential expression and methylation of brain developmental genes define location-specific subsets of pilocytic astrocytoma. *Acta Neuropathol* 2013; **126**: 291–301
- 40 Hovestadt V, Remke M, Kool M, Pietsch T, Northcott PA, Fischer R, Florence M, Cavalli G, Ramaswamy V, Zapatka M. Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. *Acta Neuropathol* 2013; **125**: 913
- 41 Sturm D, Witt H, Hovestadt V, Khuong-Quang D-A, Jones DT, Konermann C, Pfaff E, Tönjes M, Sill M, Bender S. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. *Cancer Cell* 2012; **22**: 425–37
- 42 Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. *Trends Mol Med* 2014; **20**: 460–9
- 43 Bracken CP, Scott HS, Goodall GJ. A network-biology perspective of microRNA function and dysfunction in cancer. *Nat Rev Genet* 2016; **17**: 719–32
- 44 Braoudaki M, Lambrou G, Papadodima S, Stefanaki K, Prodromou N, Kanavakis E. MicroRNA expression profiles in pediatric dysembryoplastic neuroepithelial tumors. *Med Oncol* 2016; **33**: 5
- 45 Birks DK, Barton VN, Donson AM, Handler MH, Vibhakar R, Foreman NK. Survey of MicroRNA expression in pediatric brain tumors. *Pediatr Blood Cancer* 2011; **56**: 211–16
- 46 Jones TA, Jeyapalan JN, Forshew T, Tatevossian RG, Lawson AR, Patel SN, Doctor GT, Mumin MA, Picker SR, Phipps KP, Michalski A, Jacques TS, Sheer D. Molecular analysis of pediatric brain tumors identifies microRNAs in pilocytic astrocytomas that target the MAPK and NF- κ B pathways. *Acta Neuropathol Commun* 2015; **3**: 86
- 47 Laddha SV, Nayak S, Paul D, Reddy R, Sharma C, Jha P, Hariharan M, Agrawal A, Chowdhury S, Sarkar C. Genome-wide analysis reveals downregulation of miR-379/miR-656 cluster in human cancers. *Biol Direct* 2013; **8**: 10
- 48 Skalsky RL, Cullen BR. Reduced expression of brain-enriched microRNAs in glioblastomas permits targeted regulation of a cell death gene. *PLoS ONE* 2011; **6**: e24248
- 49 Jha P, Agrawal R, Pathak P, Kumar A, Purkait S, Mallick S, Suri V, Chand Sharma M, Gupta D, Suri A. Genome-wide small noncoding RNA profiling of pediatric high-grade gliomas reveals deregulation of several miRNAs, identifies downregulation of snoRNA cluster HBII-52 and delineates H3F3A and TP53 mutant-specific miRNAs and snoRNAs. *Int J Cancer* 2015; **137**: 2343–53
- 50 Yeh W-L, Lin H-Y, Huang C-Y, Huang B-R, Lin C, Lu D-Y, Wei K-C. Migration-prone glioma cells show curcumin resistance associated with enhanced expression of miR-21 and invasion/anti-apoptosis-related proteins. *Oncotarget* 2015; **6**: 37770
- 51 Northcott PA, Fernandez-L A, Hagan JP, Ellison DW, Grajkowska W, Gillespie Y, Grundy R, Van Meter T, Rutka JT, Croce CM. The miR-17/92 polycistron is up-regulated in Sonic Hedgehog-driven medulloblastomas and induced by N-myc in Sonic Hedgehog-treated cerebellar neural precursors. *Can Res* 2009; **69**: 3249–55
- 52 Murphy BL, Obad S, Bihannic L, Ayrault O, Zindy F, Kauppinen S, Roussel MF. Silencing of the miR-17~92 cluster family inhibits medulloblastoma progression. *Can Res* 2013; **73**: 7068–78
- 53 Grunder E, D'Ambrosio R, Fiaschetti G, Abela L, Arcaro A, Zuzak T, Ohgaki H, Lv S-Q, Shalaby T, Grotzer M. MicroRNA-21 suppression impedes medulloblastoma cell migration. *Eur J Cancer* 2011; **47**: 2479–90
- 54 Baker SJ, Ellison DW, Gutmann DH. Pediatric gliomas as neurodevelopmental disorders. *Glia* 2016; **64**: 879–95
- 55 Khatua S, Wang J, Rajaram V. Review of low-grade gliomas in children – evolving molecular era and therapeutic insights. *Childs Nerv Syst* 2015; **31**: 643–52
- 56 Wiencke JK, Zheng S, Jelluma N, Tihan T, Vandenberg S, Tamgüney T, Baumber R, Parsons R, Lamborn KR, Berger MS. Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. *Neuro-Oncology* 2007; **9**: 271–9
- 57 Zhang L, Dong Y, Zhu N, Tsoi H, Zhao Z, Wu CW, Wang K, Zheng S, Ng SS, Chan FK. microRNA-139-5p exerts tumor suppressor function by targeting NOTCH1 in colorectal cancer. *Mol Cancer* 2014; **13**: 124
- 58 Song M, Yin Y, Zhang J, Zhang B, Bian Z, Quan C, Zhou L, Hu Y, Wang Q, Ni S. MiR-139-5p inhibits migration and invasion of colorectal cancer by down-regulating AMFR and NOTCH1. *Protein Cell* 2014; **5**: 851–61
- 59 Li RY, Chen LC, Zhang HY, Du WZ, Feng Y, Wang HB, Wen JQ, Liu X, Li XF, Sun Y. MiR-139 inhibits Mcl-1 expression and potentiates TMZ-induced apoptosis in glioma. *CNS Neurosci Ther* 2013; **19**: 477–83
- 60 Fan Q, He M, Deng X, Wu WK, Zhao L, Tang J, Wen G, Sun X, Liu Y. Derepression of c-Fos caused by microRNA-139 down-regulation contributes to the metastasis of human hepatocellular carcinoma. *Cell Biochem Funct* 2013; **31**: 319–24

- 61 H-d Z, L-h J, D-w S, Li J, Tang J-H. MiR-139-5p: promising biomarker for cancer. *Tumor Biol* 2015; **36**: 1355–65
- 62 Brandt WD, Schreck KC, Bar EE, Taylor I, Marchionni L, Raabe E, Eberhart CG, Rodriguez FJ. Notch signaling activation in pediatric low-grade astrocytoma. *J Neuropathol Exp Neurol* 2015; **74**: 121–31
- 63 Ajeawung NF, Faure R, Jones C, Kamnasaran D. Pre-clinical evaluation of dipotassium bisperoxo (picolinate) oxovanadate V for the treatment of pediatric low-grade gliomas. *Future Oncol* 2013; **9**: 1215–29
- 64 Ajeawung NF, Maltais R, Jones C, Poirier D, Kamnasaran D. Viability screen on pediatric low grade glioma cell lines unveils a novel anti-cancer drug of the steroid biosynthesis inhibitor family. *Cancer Lett* 2013; **330**: 96–105
- 65 Bax DA, Little SE, Gaspar N, Perryman L, Marshall L, Viana-Pereira M, Jones TA, Williams RD, Grigoriadis A, Vassal G. Molecular and phenotypic characterisation of paediatric glioma cell lines as models for pre-clinical drug development. *PLoS ONE* 2009; **4**: e5209
- 66 Henriquez NV, Forsheu T, Tatevossian R, Ellis M, Richard-Loendt A, Rogers H, Jacques TS, Reitboeck PG, Pearce K, Sheer D. Comparative expression analysis reveals lineage relationships between human and murine gliomas and a dominance of glial signatures during tumor propagation in vitro. *Can Res* 2013; **73**: 5834–44
- 67 Upadhyaya SA, Ghazwani Y, Wu S, Broniscer A, Boop FA, Gajjar A, Qaddoumi I. Mortality in children with low-grade glioma or glioneuronal tumors: a single-institution study. *Pediatr Blood Cancer* 2017; **65**: e26717

Supporting information

Additional Supporting Information may be found in the online version of this article at the publisher's web-site:

Figure S1. Hierarchical clustering of microRNAs displaying differential expression in pLGGs vs. pHGGs

Hierarchical clustering of the 60 microRNAs differentially expressed in pLGGs vs. pHGGs.

Figure S2. Expression of PIK3CA in pLGG tissues.

Figure S3. Expression of the senescence marker SA- β -gal in patient-derived primary pLGG cells.

Figure S4. Methylation profile and copy number variation (CNV) of primary patients' derived pLGG cells shows a close similarity to the primary tumour.

Figure S5. Levels of miR-139-5p before and after its overexpression in the four primary pLGG cell lines (derived from an AG, two DNETs, and a GG).

Figure S6. Expression of p-p70 S6K in pLGG tissues.

Figure S7. Expression of p-AKT in pLGG tissues.

Table S1. MicroRNAs displaying significantly upregulated expression in pLGG tissues relative to non-neoplastic brain (CTRL).

Table S2. MicroRNAs displaying significantly down-regulated expression in pLGG tissues relative to non-neoplastic brain (CTRL).

Table S3. MicroRNAs displaying significantly upregulated expression in infratentorial pLGGs with respect to normal cerebellum (CTRL).

Table S4. MicroRNAs displaying significantly down-regulated expression in infratentorial pLGGs with respect to normal cerebellum (CTRL).

Table S5. MicroRNAs expressed at significantly higher levels in pLGG tissues than in pHGG.

Table S6. MicroRNAs expressed at significantly lower levels in pLGG tissues than in pHGG.

Appendix S1. Materials and methods.

Received 21 September 2017

Accepted after revision 6 February 2018

Published online Article Accepted on 25 February 2018